Humedics Receives Patent on Method for Quantitative Liver Function Analysis
News Apr 16, 2013
Humedics GmbH has announced that another key patent protecting Humedics’ proprietary technology has been granted by Australian authorities.
The Australian patent AU20062664108 covers an analysis method for determining a functional parameter of an organ using a 13C labeled methacetin solution.
“This patent is a milestone for the commercialization of our LiMAx test and the corresponding FLIP device”, says Prof. Dr. Karsten Heyne, co-founder of Humedics GmbH.
Prof. Heyne continued, “We receive so much positive feedback on this test system from clinical users and, from a company perspective, it is great that the essential part of our proprietary technology is protected by now.”
The underlying principle of the test involves the following steps: At first, a13Cmethacetin solution is administered intravenously. Methacetin is metabolized in the liver to paracetamol and 13CO2 and the latter is exhaled in the breath.
The exhaled air is collected via a respiratory mask. Subsequent measurement of 13CO2 in a detection device provides a quantitative determination of the liver capacity and thus the liver function.
“Liver surgery and liver transplantation often are very serious interventions” says Dr. Martin Stockmann, co-founder of Humedics GmbH and co-owner of the mentioned patent. “It is therefore a high medical need to determine liver function prior to this kind of interventions to better assess the prognosis and also after interventions to monitor recovery.”
The LiMAx test fulfills these requirements. Liver diagnostic tests available on the market so far are of limited use for this purpose and do not provide a quantitative liver function analysis.
The LiMAx test is a bedside test that can be performed prior, during and subsequent to surgery. And the liver surgeon at Charité - Universitätsmedizin Berlin adds: “In liver surgery the LiMAx test provides added value to make correct therapeutic decisions and to improve therapy control.”
The recently granted patent adds to Humedics’ portfolio of pending and granted patents that secures the economic utilization of the company’s products.
A previously granted patent covers the measurement device and a method for analyzing a sample gas by infrared absorption (German Patent No 102009055320) and thus Humedics’ FLIP device for the measurement of exhaled air.
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Material From Shellfish Boosts Sensitivity of Diagnostic TestsNews
By adding polydopamine at a key step, the sensitivity of diagnostic tests and bioassays can be increased by as many as 100 to 1,000 times.READ MORE